RxDoctor Payments DataLook up a doctor →

Andrew Trainer, MD

Urology · Omaha, NENPI 1477556561

Payments from drug & device makers

$851,763in general payments, 2019–2025

Across 794 payments — averaging $1072.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dendreon Pharmaceuticals LLC$214K
  • Janssen Research & Development, LLC$154K
  • Procept Biorobotics Corporation$96K
  • Ferring Pharmaceuticals AS$69K
  • Astellas Pharma Global Development$65K
  • E.r. Squibb & Sons, L.L.C.$54K
  • plus $198K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Dendreon Pharmaceuticals LLC58$214,456
Janssen Research & Development, LLC56$154,225
Procept Biorobotics Corporation29$95,962
Ferring Pharmaceuticals AS9$69,320
Astellas Pharma Global Development19$65,390
E.r. Squibb & Sons, L.L.C.6$54,078
Pfizer27$47,858
Sumitomo Pharma America, Inc.114$38,063
Laborie Medical Technologies Corp.7$35,440
OPKO Pharmaceuticals, LLC6$24,019
Bayer37$18,863
Urogen Pharma, Inc.32$18,715
Spectrum Pharmaceuticals Inc.2$5,281
C. R. Bard, Inc. & Subsidiaries1$1,581
AbbVie(2 entities)69$1,134
Axonics, Inc.36$907
Johnson & Johnson(2 entities)55$878
Novartis7$823
Astellas Pharma US Inc33$598
Medtronic(2 entities)13$402
Myovant Sciences Inc.37$323
Neotract Inc.8$321
Urovant Sciences Inc7$290
Merck12$289
Ferring Pharmaceuticals Inc.8$264
Endo Pharmaceuticals Inc.12$247
Tolmar, Inc.10$214
Verity Pharmaceuticals Inc.11$191
Accord Healthcare, Inc.6$174
Amgen10$155
AstraZeneca1$125
Myriad Genetic Laboratories, Inc.7$116
Boston Scientific6$114
Blue Earth Diagnostics5$79
Seagen Inc.1$79
Dornier Medtech America, Inc2$75
Teleflex LLC3$74
Olympus America Inc.3$69
Coloplast4$66
Innovation Technologies Inc1$66
Progenics Pharmaceuticals, Inc.2$62
Antares Pharma, Inc.2$34
Sun Pharmaceutical Industries Inc.2$32
Tolmar Pharmaceuticals, Inc.2$31
Calyxo, Inc.1$25
KARL Storz Endoscopy-america1$23
GE HealthCare1$22
Foundation Medicine, Inc.1$21
Vertex1$20
Alnylam Pharmaceuticals Inc.1$20
Novo Nordisk1$19
Pacira Pharmaceuticals Incorporated1$19
Cook Medical LLC1$17
Kowa Pharmaceuticals America, Inc.1$14
Duchesnay USA Incorporated1$14
Siemens Medical Solutions USA, Inc.1$13
Telix Pharmaceuticals1$13
Medline Industries LP1$13
Therapeuticsmd, Inc.1$12
180 Medical, Inc.1$11

How this compares

$851,763 in reported general payments places this provider in the 95th percentile of 79 urology providers in Nebraska.

See all urology providers in Nebraska

Medicare billing

Part B allowed, 2024
$766,709
Medicare patients
1,086
Services billed
50,799

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other urology in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →